Stock comparison
Dynavax Technologies
ResMed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
DVAX
Dynavax Technologies
Market cap
$1.82B
Sector
Healthcare
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | DVAX | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 38D | 72B | RMD |
| Benjamin Graham | 59D | 75B | RMD |
| Philip Fisher | 56C | 75B | RMD |
| Peter Lynch | 50C | 58C | RMD |
| Joel Greenblatt | 2F | 47D | RMD |
| Charlie Munger | 40D | 69B | RMD |
| Terry Smith | 48D | 73B | RMD |
Side-by-side metrics
| Metric | DVAX | RMD |
|---|---|---|
| Market cap | $1.82B | $30.18B |
| P/E (TTM) | - | 19.6x |
| EV/EBIT | - | 17.1x |
| ROIC (TTM) | 1.19% | 19.63% |
| Gross margin | 83.17% | 61.69% |
| Net margin | -13.13% | 27.44% |
| Revenue CAGR 5y | 56.22% | 12.64% |
| EPS CAGR 5y | - | 30.73% |
| Debt / Equity | 0.5x | 0.1x |
| Dividend yield | 0.0% | 1.14% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
DVAX leads on
- P/E (TTM)-vs 19.6x+147%
- EV/EBIT-vs 17.1x+104%
- Revenue CAGR 5y56.22%vs 12.64%+78%
- Gross margin83.17%vs 61.69%+26%
RMD leads on
- Net margin27.44%vs -13.13%+148%
- Dividend yield1.14%vs 0.0%+100%
- Market cap$30.18Bvs $1.82B+94%
- ROIC (TTM)19.63%vs 1.19%+94%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.